PHOENIX--(BUSINESS WIRE)--INSYS Therapeutics/NeoPharm (Other OTC: NEOL.PK) announces the inclusion of Daniel D. Von Hoff, M.D., F.A.C.P. to their management team as Chief Development Officer. Dr. Von Hoff also currently serves as Physician in Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and for Scottsdale Healthcare. He holds an appointment as Clinical Professor of Medicine, University of Arizona, College of Medicine.
Dr Von Hoff is the founder of ILEX™ Oncology, Inc. (acquired by Genzyme) as well as founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and Editor-in-Chief of Molecular Cancer Therapeutics. Additionally, he is a co-founder of the AACR/ASCO Methods in Clinical Cancer Research Workshop. He was appointed to President Bush’s National Cancer Advisory Board in 2004-2010, is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology.
Dr. Von Hoff is the recipient of the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research. His major interest is in the development of new anticancer agents, both in the clinic and in the laboratory and he has been involved in the beginning of the development of multiple regularly used agents.
Dr Von Hoff states, “It is clear that supportive care including pain control, improving appetite and muscle mass are critical for the survival of patients with cancer. I am very pleased to be working with a team that has such a drive to make a difference in that area of patient care.”
Michael Babich, President and COO of INSYS/NeoPharm, adds, “We are delighted to have someone with the expertise in oncology and supportive care that Dan embodies join our management team. Dan’s vision and ability to bring oncology drugs to the marketplace is unmatched and his addition will strengthen our oncology focus.”
About INSYS Therapeutics, Inc.
INSYS Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative products that address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders. We develop new formulations and delivery methods for existing drugs in order to achieve enhanced efficacy, faster onset of action, reduced side effects, convenient delivery and increased patient compliance. Our drug development programs are based on existing compounds with known or proven safety, efficacy and commercialization histories. We are focused on leveraging our expertise in the expanding synthetic cannabinoid derivatives and specialized opioid markets to build a portfolio of proprietary products that address the limitations of existing therapies.